Breakthrough in breast cancer treatment: Enhertu receives FDA approval as first-line drug
Kyiv • UNN
The FDA has approved Enhertu from AstraZeneca and Daiichi Sankyo for the first-line treatment of HER2-positive breast cancer. The combination with Perjeta extended progression-free survival and reduced tumors in 87% of patients.
The US Food and Drug Administration (FDA) has approved Enhertu from AstraZeneca and Daiichi Sankyo for use as a first-line treatment for a type of breast cancer. This was reported by Reuters, writes UNN.
Details
The approval allows Enhertu to be used in combination with Roche's Perjeta for the treatment of adults with advanced HER2-positive breast cancer.
Enhertu is an antibody-drug conjugate that effectively delivers chemotherapy directly to HER2-positive cancer cells while minimizing damage to healthy tissues.
The approval is based on the results of a clinical trial of 1157 patients, where the combination of Enhertu and Perjeta extended the median progression-free survival to 40.7 months versus 26.9 months for standard treatment. Tumors shrank or disappeared in 87% of patients receiving the new combination.
Enhertu was previously approved for the treatment of breast cancer as a third-line drug, as well as for the treatment of some types of stomach and lung cancer.